drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (allogeneic CAR T-cell)
drug_description
Allogeneic CD19-directed CAR T-cell therapy using donor T cells engineered to target CD19 on B cells, leading to T-cell activation and cytotoxic elimination of malignant B cells and minimal residual disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor T cells engineered to express a CD19‑specific chimeric antigen receptor recognize CD19 on B cells, leading to T‑cell activation, proliferation, and cytotoxic elimination of malignant B cells to eradicate minimal residual disease.
drug_name
Cemacabtagene ansegedleucel (cema-cel)
nct_id_drug_ref
NCT06500273